Inherited epidermolysis bullosa (EB) consists of a number of genetically heterogeneous skin diseases characterised by defects in the synthesis of proteins involved in the adhesion of the epidermis to the dermis. The common clinical manifestations of EB are mechanical fragility of the skin, blister formation, and abnormal wound healing, but the severity of the skin lesions varies depending on the distinct type of the disease. Junctional EB and dystrophic EB (DEB), the most severe types of EB diseases, usually cause chronic pain and discomfort that can significantly reduce the quality of life of affected patients. In addition, non-healing wounds can cause severe systemic infections, malnutrition, and growth inhibition, and may promote carcinogenesis in some cases. Wound care is, therefore, of critical importance in the management of EB. However, the current treatments for EB, including the most recently suggested approaches, are not always effective or satisfactory